Advice
Following a full submission
budesonide/formoterol turbohaler (Symbicort® SMART®) is accepted for use within NHS Scotland, in adults, for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting beta2-agonist) is appropriate; Symbicort is taken as regular maintenance treatment and as needed in response to symptoms.
In patients using inhaled budesonide/formoterol as preventer therapy, use of the same inhaler for reliever therapy is associated with a longer time to first severe exacerbation than use of comparator reliever regimens. In addition, some patients may be able to reduce the dose of preventer therapy.
Download detailed advice123KB (PDF)
Medicine details
- Medicine name:
- budesonide/formoterol 100/6, 200/6 turbohaler (Symbicort SMART)
- SMC ID:
- 362/07
- Indication:
- Asthma
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 June 2007